Bringing the fundamentals into focus…
Back to Inhibrx Biosciences, Inc.
How Inhibrx Biosciences, Inc. stacks up
INBX · against 420 other Healthcare companies of similar size
Growth
11/ 100
Near the bottom of its peers.
Ranked #375 of 421 · scores higher than 10% of peers
Bars: peers in each 10-point band of the growth score44 peers with a growth score of 10–19, including INBX · Click a bar to see the companies
Why growth scores 11?
Weighted metrics compared with all Healthcare companies.Mainly because of its revenue growth and 3-year revenue growth, which are weaker than most Healthcare peers.
- slower revenue growth over the last year: weaker than 100% of peers. Revenue growth: -100.0% vs peer median 6.1%
- slower revenue growth over three years: weaker than 71% of peers. 3-year revenue growth: -0.0% vs peer median 5.8%
- Still loss-making, but the loss per share narrowed. Earnings per share growth: — vs peer median 9.8%
Metric by metric
Position: dot = INBX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | INBX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 427 reported | -100.0% | 5.2% | 0% | 33% | |
| Earnings per share growthHigher is better · 238 reported | Not reported | 7.4% | — | — | 33% |
| 3-year revenue growthHigher is better · 414 reported | -0.0% | 5.8% | 30% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around INBX| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 1 | 1.4B USD | 99 | 73 | |
| 1 | 2.1B USD | 99 | 96 | |
| 1 | 885M USD | 99 | 33 | |
| 1 | 15.6B DKK (≈$2.3B) | 99 | 96 | |
| 370 | 14.2B CNY (≈$2.0B) | 12 | 10 | |
| 375 | 9.5B CNY (≈$1.3B) | 11 | 45 | |
| 375 | 6.5B CNY (≈$911M) | 11 | 62 | |
| 375 | 143.3B JPY (≈$975M) | 11 | 61 | |
| 375 | 1.2B USD | 11 | 6 | |
| 379 | 6.7B CNY (≈$938M) | 10 | 30 | |
| 379 | 6.2B CNY (≈$861M) | 10 | 35 | |
| 379 | 15.0B CNY (≈$2.1B) | 10 | 55 | |
| 379 | 6.8B CNY (≈$946M) | 10 | 21 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score